Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

The Emerging Cancer Vaccine Market

Published by: Kalorama Information

Published: Feb. 1, 2004 - 226 Pages


Table of Contents



Chapter One: Executive Summary

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors


Chapter Two: The Emerging Cancer Vaccine Market

  • History and Growth of the Cancer Treatment Market
  • Cancer Vaccine Technology
  • Industry Structure
  • Demographics and Statistics


Chapter Three: Current Cancer Vaccine Market

  • Overview
  • Description of Cancers with Available Vaccines
    • Bladder Cancer
    • Colorectal Cancer
    • Melanoma


  • Description of Products
    • TheraCys (ImmuCyst)
    • M-Vax
    • Melacine
    • OncoVax
    • Pacis


  • Market Size and Growth
  • Competitive Analysis


Chapter Four: Emerging Cancer Vaccine Potential

  • Overview
    • Description of Cancers with Potential Vaccines
      • Breast Cancer
      • Cervical Cancer
      • Colorectal Cancer
      • Gastrointestinal Cancer
        • Stomach


        • Liver
        • Pancreas


      • Kidney
      • Leukemia
      • Lung Cancer
      • Lymphoma
      • Melanoma
      • Multiple Myeloma
      • Neuroblastoma
      • Ovarian Cancer
      • Prostate Cancer
      • Sarcoma


  • Cancer Vaccine Pipeline
    • Phase III
    • Phase II
    • Phase I


  • Market and Product Launch Forecasts
  • Potential Competitors and Analysis, 2008


Chapter Five: Issues and Trends Affecting the Cancer Vaccine Market

  • Introduction
  • Early Detection and Screening
  • Insurance and Reimbursement Issues
  • Personalized Medicine
  • Pharmacogenomics
  • Vaccine Strategies
  • New Genetic Technique
  • New application for Tobacco Plant


Chapter Six: The Emerging Cancer Vaccine Market: Total Market Size and Forecast

  • Overview
  • Total Market Size and Forecast
  • Competitor Analysis
  • Market Analysis


Chapter Seven: Corporate Profiles

  • AVAX Technologies, Inc.
  • Aventis Pasteur, Inc.
  • Corixa Corporation
  • Intracel Holdings Corporation
  • Shire Biochem, Inc.


Chapter Eight: Emerging Vaccine Corporate Profiles

  • Advaxis, Inc.
  • Aphton Corporation
  • Antigenics, Inc.
  • AVI BioPharma, Inc.
  • Berlex, Inc.
  • Biomira, Inc.
  • Biovest International, Inc.
  • CancerVax Corporation
  • Cell Genesys, Inc.
  • CYTOGEN Corporation
  • Dendreon Corporation
  • Epimmune, Inc.
  • Favrille, Inc.
  • GeneMax Corporation
  • Genitope Corporation
  • Genzyme Molecular Oncology
  • Geron Corporation
  • GlaxoSmithKline plc
  • IDM, S.A.
  • ImClone Systems, Inc.
  • Immune Response Corporation, The
  • Large Scale Biology Corporation
  • Medarex, Inc.
  • MedImmune, Inc.
  • Merck & Company, Inc.
  • Northwest Biotherapeutics, Inc.
  • Oxford BioMedica plc
  • Progenics Pharmaceuticals, Inc.
  • Therion Biologics Corporation
  • Titan Pharmaceuticals, Inc.
  • Transgene S.A.
  • United Biomedical, Inc.
  • Vical, Inc.
  • Wyeth
  • YM BioSciences, Inc.


Appendix A: Company Names and Addresses

Appendix B: Regulatory Authorities
and Organizations




List of Exhibits


Chapter One: Executive Summary

  • Table 1-1: Current and Emerging Market - Cancer Vaccines, 2001-2008
  • Figure 1-1: Current and Emerging Market - Cancer Vaccines, 2001-2008


Chapter Two: The Emerging Cancer Vaccine Market

  • Table 2-1: Estimated and Projected World Cancer Incidence
    by Common Type of Cancer, 2003 and 2020
  • Figure 2-1: Estimated and Projected World Cancer Incidence
    by Common Type of Cancer, 2003 and 2020
  • Table 2-2: Estimated and Projected World Cancer Mortality
    by Common Type of Cancer, 2003 and 2020
  • Figure 2-2: Estimated and Projected World Cancer Mortality
    by Common Type of Cancer, 2003 and 2020
  • Table 2-3: World Population by Selected Geographical Region, 2003-2050
  • Figure 2-3: World Population by Selected Geographical Region, 2003-2050
  • Table 2-4: Estimated World Population by Age and Geographical Region, 2003
  • Figure 2-4: Estimated World Population by Age and Geographical Region, 2003
  • Table 2-5: Life Expectancy at Birth by Selected Countries, 2000
  • Table 2-6: United States Life Expectancy at Birth, 1990-2000,
    and Projections, 2005-2010
  • Figure 2-5: United States Average Years of Life Lost Per Person Dying of Cancer,
    All Races, Both Sexes, 2000
  • Figure 2-6: United States Estimated Person-Years of Life Lost Due to Cancer,
    All Races, Both Sexes, 2000


Chapter Three: Current Cancer Vaccine Market

  • Table 3-1: Malignant Conditions Of The Skin
  • Table 3-2: Cancer Vaccines: Estimated World Incidence and Mortality of Cancers
    with Potential Vaccines
  • Figure 3-1: Cancer Vaccines: Estimated World Incidence and Mortality of Cancers
    with Potential Vaccines
  • Table 3-3: Current Cancer Vaccines Market, 2001-2008
  • Figure 3-2: Current Cancer Vaccines Market, 2001-2008
  • Table 3-4: Leading Suppliers Shares by Market Revenues, Estimated 2003
  • Figure 3-3: Leading Suppliers Market Share, Estimated 2003


Chapter Four: Emerging Cancer Vaccine Potential

  • Table 4-1: Types of Leukemia
  • Table 4-2: Types of Primary Lung Cancer
  • Table 4-3: Classification of Non-Hodgkin’s Lymphomas
  • Table 4-4: Malignant Conditions of The Skin
  • Table 4-5: Cancer Vaccines: Estimated World Incidence and Mortality of Cancers
    with Potential Vaccines
  • Figure 4-1: Cancer Vaccines: Estimated World Incidence and Mortality of Cancers
    with Potential Vaccines
  • Table 4-6: Cancer Vaccines in the Pipeline
  • Table 4-7: Cancer Vaccines: Emerging Cancer Vaccines Market, 2004-2008
  • Figure 4-2 Cancer Vaccines: Emerging Cancer Vaccines Market, 2004-2008
  • Table 4-8: Cancer Vaccines: Emerging Cancer Vaccines Market
    by Type, 2004-2008
  • Table 4-9: Cancer Vaccines: Emerging Cancer Vaccines Market by
    Type - Revenues and Percent Distribution, 2004-2008
  • Figure 4-3: Cancer Vaccines: Emerging Cancer Vaccines Market by Type -
    Revenues and Percent Distribution, 2004-2008
  • Figure 4-4: Cancer Vaccines: Emerging Cancer Vaccines Market
    by Percent Distribution, 2004-2008
  • Figure 4-5: Cancer Vaccines: Emerging Cancer Vaccines Market
    by Percent andProduct Type, 2008
  • Table 4-10: Leading Suppliers Shares by Market Revenues,
    Based on Emerging Vaccines - Projected 2008
  • Figure 4-6: Leading Suppliers Shares by Market Revenues,
    Based on Emerging Vaccines - Projected 2008
  • Table 4-11: Competitors by Cancer Vaccine Type, Based on
    Emerging Vaccines - Projected 2008
  • Figure 4-7: Competitors by Cancer Vaccine Type, Based on
    Emerging Vaccines - Projected 2008


Chapter Five: Issues and Trends Affecting the Cancer Vaccine Market

  • Table 5-1: Cancer Detection Tests


Chapter Six: The Emerging Cancer Vaccine Market: Total Market Size and Forecast


  • Table 6-1: Cancer Vaccines, 2001-2008
  • Figure 6-1: Cancer Vaccines, 2001-2008
  • Table 6-2: Cancer Vaccines by Current and Emerging Markets, 2001-2008
  • Table 6-3: Cancer Vaccines by Current and Emerging Market Revenues
    and Percent Distribution, 2001-2008
  • Figure 6-2: Cancer Vaccines by Current and Emerging Market Revenues
    and Percent Distribution, 2001-2008
  • Figure 6-3: Cancer Vaccines Current and Emerging Markets
    by Percent Distribution, 2001-2008
  • Figure 6-4: Current and Emerging Cancer Vaccines Market
    by Percent, 2008
  • Table 6-4: Cancer Vaccines: Current and Emerging Suppliers
    and Developers of Cancer Vaccines by Cancer Type
  • Figure 6-5: Cancer Vaccines: Competitors by Cancer Vaccine Type
    and Number of Products Available or in Development
  • Figure 6-6: Cancer Vaccines: Cancer Vaccines Available or in
    Development by Cancer Type, 2003
  • Figure 6-7:Cancer Vaccines: Competitors by Cancer Vaccine Availability
    and/or Number of Vaccines in Development
  • Figure 6-8: Cancer Vaccines: Competitors by Cancer Vaccine Availability
    and/or Number of Vaccines in Development



Abstract

Immunologic approaches to cancer therapy are not only increasing in reputation and number, but the market for these products is increasingly becoming a reality. Vaccines are in the forefront of this approach to cancer, and the handful of cancer vaccine products currently on the market for bladder, colon, and skin cancer are soon to be joined by many more with indications for more wide-spread forms, including lung, breast, ovarian, prostate, leukemia, and others.

This new study from Kalorama discusses the emerging vaccine technologies and the competitive and clinical landscape in which they will emerge. Extensive interviewing of industry participants has revealed the revenues of the existing competitors that we belive have never been published, and market models based on epidemiology, likely clinical acceptance, and regulatory events and validated with this existing revenue information predicts market size, growth, and share for emerging products in the United States and the world through 2008.

Get Full Details About This Report >>

US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Available by the section

Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008